Gatekeepers for pragmatic clinical trials

被引:26
|
作者
Whicher, Danielle M. [1 ]
Miller, Jennifer E. [2 ,3 ]
Dunham, Kelly M. [1 ]
Joffe, Steven [4 ]
机构
[1] Patient Ctr Outcomes Res Inst, Washington, DC 20036 USA
[2] Duke Univ, Kenan Inst Eth, Durham, NC USA
[3] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA
[4] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
Gatekeeper; research ethics; pragmatic clinical trial; comparative effectiveness research; deliberative democracy; RANDOMIZED CONTROLLED-TRIALS; HEALTH RESEARCH; DESIGN; PRECIS;
D O I
10.1177/1740774515597699
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
To successfully implement a pragmatic clinical trial, investigators need access to numerous resources, including financial support, institutional infrastructure (e.g. clinics, facilities, staff), eligible patients, and patient data. Gatekeepers are people or entities who have the ability to allow or deny access to the resources required to support the conduct of clinical research. Based on this definition, gatekeepers relevant to the US clinical research enterprise include research sponsors, regulatory agencies, payers, health system and other organizational leadership, research team leadership, human research protections programs, advocacy and community groups, and clinicians. This article provides a framework to help guide gatekeepers' decision-making related to the use of resources for pragmatic clinical trials. Relevant ethical considerations for gatekeepers include (1) concern for the interests of individuals, groups, and communities affected by the gatekeepers' decisions, including protection from harm and maximization of benefits; (2) advancement of organizational mission and values; and (3) stewardship of financial, human, and other organizational resources. Separate from these ethical considerations, gatekeepers' actions will be guided by relevant federal, state, and local regulations. This framework also suggests that to further enhance the legitimacy of their decision-making, gatekeepers should adopt transparent processes that engage relevant stakeholders when feasible and appropriate. We apply this framework to the set of gatekeepers responsible for making decisions about resources necessary for pragmatic clinical trials in the United States, describing the relevance of the criteria in different situations and pointing out where conflicts among the criteria and relevant regulations may affect decision-making. Recognition of the complex set of considerations that should inform decision-making will guide gatekeepers in making justifiable choices regarding the use of limited and valuable resources.
引用
收藏
页码:442 / 448
页数:7
相关论文
共 50 条
  • [1] Pragmatic Clinical Trials
    Mehmood, Muddassir
    [J]. JACC-HEART FAILURE, 2021, 9 (08) : 606 - 606
  • [2] Pragmatic Clinical Trials
    Doorenbos, Ardith Z.
    Chae, Duckhee
    [J]. JOURNAL OF KOREAN ACADEMY OF NURSING, 2022, 52 (05) : 477 - 478
  • [3] Pragmatic clinical trials
    MacPherson, H
    [J]. COMPLEMENTARY THERAPIES IN MEDICINE, 2004, 12 (2-3) : 136 - 140
  • [4] Making Pragmatic Clinical Trials More Pragmatic
    Platt, Richard
    Bosworth, Hayden B.
    Simon, Gregory E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [5] TRENDS IN PRAGMATIC CLINICAL TRIALS
    Kloc, K.
    Pisarczyk, K.
    Lach, S.
    Remuzat, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A772 - A772
  • [6] Pragmatic Clinical Trials in Osteoporosis
    Giovanni Adami
    Kenneth G. Saag
    Maria I. Danila
    [J]. Current Osteoporosis Reports, 2019, 17 : 521 - 526
  • [7] Pragmatic Clinical Trials in Osteoporosis
    Adami, Giovanni
    Saag, Kenneth G.
    Danila, Maria I.
    [J]. CURRENT OSTEOPOROSIS REPORTS, 2019, 17 (06) : 521 - 526
  • [8] Clinical trials: conventional or pragmatic?
    Tavazzi, Luigi
    Maggioni, Aldo P.
    Rapezzi, Claudio
    Ferrari, Roberto
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (04) : 596 - 599
  • [9] Clinical Trials Overview: From Explanatory to Pragmatic Clinical Trials
    Le-Rademacher, Jennifer
    Gunn, Heather
    Yao, Xiaoxi
    Schaid, Daniel J.
    [J]. MAYO CLINIC PROCEEDINGS, 2023, 98 (08) : 1241 - 1253
  • [10] Pragmatic clinical trials and observational studies
    Trojano, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 60 - 60